Condition: Locally Advanced Solid Tumors · Metastatic Solid Tumors · Lymphoma · Sponsor: Turning Point Therapeutics, Inc.
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
This description comes directly from the study's public registry record.
BMS Study Connect Contact Center www.BMSStudyConnect.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain the NCT# and Site #.
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California at Los Angeles | Los Angeles, California, United States | Recruiting |
| Children's Hospital Colorado - Anschutz Medical Campus | Aurora, Colorado, United States | Recruiting |
| Local Institution - 2105 | Orlando, Florida, United States | Completed |
| Local Institution - 2120 | Orlando, Florida, United States | Completed |
| Children's Healthcare of Atlanta - Egleston Hospital | Atlanta, Georgia, United States | Recruiting |
| Maine Medical Center | Scarborough, Maine, United States | Recruiting |
| Dana Farber Cancer Institute. | Boston, Massachusetts, United States | Recruiting |
| Washington University School of Medicine in St. Louis | St Louis, Missouri, United States | Recruiting |
| Local Institution - 2110 | New Brunswick, New Jersey, United States | Completed |
| Local Institution - 2102 | New York, New York, United States | Completed |
| Levine Children's Hospital- Pediatric Neuro-Oncology | Charlotte, North Carolina, United States | Recruiting |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04094610